Investor Relations

Advancing and building value

Investor Hub

Latest Press Releases

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General HospitalSt. Michael’s Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites in North America ...

Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention ...

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics ...
The Press Releases page is the starting place for recent advances, new patents, corporate filings, information for investors and all progress updates on active clinical trials.
  • Browse all of the company’s material news releases.
  • Read the latest releases when they are published here or via email by subscribing to email alerts and news.
Corporate Presentation

August 2025

Learn more about Arch Biopartners’ clinical progress and corporate strategy in the latest corporate presentation (PDF) .

Investor Information

Find corporate details, analyst coverage, regulatory filings, financial reports, and links our SEDAR+ profile.

Arch Biopartners key stock indicators, price, volume and all historical data.

The Stock Performance page presents the current and historical data for both of the Arch Biopartners securities symbols on the TSX Venture Exchange and the OTCQB Venture Exchange.

The company’s reports and filings include current filings as well as an archive for investors and the public for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .

Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Press Release Archives